PensionDanmark Pensionsforsikringsaktieselskab Grows Stake in Amgen Inc. $AMGN

PensionDanmark Pensionsforsikringsaktieselskab raised its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 12.3% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 108,300 shares of the medical research company’s stock after purchasing an additional 11,821 shares during the period. PensionDanmark Pensionsforsikringsaktieselskab’s holdings in Amgen were worth $39,218,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the business. Anfield Capital Management LLC raised its stake in Amgen by 1,000.0% in the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after buying an additional 70 shares during the last quarter. Dogwood Wealth Management LLC grew its stake in shares of Amgen by 275.0% during the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after acquiring an additional 55 shares during the last quarter. Tower View Wealth Management LLC increased its holdings in shares of Amgen by 331.6% during the first quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 63 shares in the last quarter. Manning & Napier Advisors LLC increased its holdings in shares of Amgen by 49.2% during the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after acquiring an additional 32 shares in the last quarter. Finally, Ares Financial Consulting LLC purchased a new position in shares of Amgen in the 4th quarter valued at approximately $34,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Price Performance

Shares of NASDAQ AMGN opened at $404.85 on Friday. Amgen Inc. has a 52 week low of $269.77 and a 52 week high of $418.40. The business’s 50 day moving average price is $361.29 and its 200 day moving average price is $355.86. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 4.44. The firm has a market cap of $218.50 billion, a P/E ratio of 25.16, a P/E/G ratio of 4.10 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The company had revenue of $10.05 billion during the quarter, compared to analyst estimates of $9.43 billion. During the same period last year, the firm posted $6.02 EPS. Amgen’s revenue for the quarter was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, sell-side analysts expect that Amgen Inc. will post 22.47 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 21st will be paid a $2.52 dividend. The ex-dividend date is Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.5%. Amgen’s dividend payout ratio is presently 70.15%.

Wall Street Analyst Weigh In

AMGN has been the subject of a number of recent analyst reports. BMO Capital Markets lifted their target price on shares of Amgen from $400.00 to $450.00 and gave the stock an “outperform” rating in a research note on Wednesday. Wall Street Zen lowered shares of Amgen from a “buy” rating to a “hold” rating in a research note on Saturday, June 27th. Scotiabank raised their price target on shares of Amgen from $385.00 to $450.00 and gave the stock an “outperform” rating in a report on Wednesday. Daiwa Securities Group lowered their price objective on shares of Amgen from $410.00 to $390.00 and set an “outperform” rating for the company in a research note on Wednesday, May 13th. Finally, Cantor Fitzgerald reissued a “neutral” rating and set a $350.00 price objective on shares of Amgen in a report on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, fifteen have given a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $367.93.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported second-quarter revenue of $10.05 billion, up approximately 9.5% year over year, while adjusted EPS of $6.29 exceeded the roughly $5.62 analyst consensus. Growth across cardiovascular, bone-health, and rare-disease medicines helped offset pressure from older products facing biosimilar competition. Amgen second-quarter sales rise 9%, profit tops Street view
• Positive Sentiment: Management raised its 2026 outlook, with adjusted EPS guidance of $22.30 to $23.50 and revenue guidance of approximately $38.2 billion to $39.4 billion. The update reflects momentum across Amgen’s portfolio and continued progress in its late-stage pipeline. AMGN Beats on Q2 Earnings, Lifts Outlook Despite Legacy Drug Pressure
• Positive Sentiment: Several firms raised their targets following the results. UBS lifted its target to $440 and TD Cowen to $452, while BMO, Oppenheimer, and Scotiabank set targets near $450 or higher; UBS and TD Cowen maintained bullish ratings. Amgen Price Target Raised to $440 at UBS
• Neutral Sentiment: Analyst sentiment remains divided. Citi maintained a Hold rating, while UBS retained Buy; other firms raised targets but kept Hold, Equal Weight, or Underperform ratings, suggesting some analysts believe the upgraded outlook is already reflected in the valuation. Citi Keeps Their Hold Rating on Amgen
• Negative Sentiment: Amgen abandoned an obesity-drug candidate, while pressure from biosimilars and weaker performance in some legacy franchises remains a headwind. Questions surrounding Tavneos clinical data add regulatory and reputational uncertainty. Amgen Stock Climbs as Drug Growth Outruns Obesity Setback
• Negative Sentiment: A reported patient-data breach has prompted a law-firm investigation into potential privacy claims, creating additional legal, operational, and reputational risk for Amgen. Amgen Data Breach Class Action Investigation

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.